Oppenheimer Starts Amarin Corporation (AMRN) at Underperform, $7 PT
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Gilead Sciences (GILD) 'Quietly' Added Amarin's (AMRN) Vascepa to an Old NASH Combo Trial - Raymond James
November 19, 2019 5:38 PM ESTRaymond James analyst Steven Seedhouse highlighted that Gilead Sciences (NASDAQ: GILD) has "quietly" added Amarin's (NASDAQ: AMRN) Vascepa to an old NASH combo trial.
The analyst commented, "We recently noticed a change to the clinical... More
Amarin Corp. (AMRN) Declines After Shares Hit with 'Underperform' Rating
November 19, 2019 4:29 PM ESTAmarin Corp. (NASDAQ: AMRN) declined post-market-close Tuesday after the stock was initiated with an Underperform rating and a price target of $7 at Oppenheimer. The stock declined about 3.5%.
... More